Is JAGX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Future Pak license and non-dilutive cash, with q1 2026 revenue at ~$20.3 million, but almost entirely a one-time ~$19 million license fee, not recurring sales. The bear case rests on the dominant risks are financing and dilution. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risks are financing and dilution. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Future Pak license and non-dilutive cash. The January 2026 US license deal with Woodward Specialty, a Future Pak affiliate, is the near-term story.

The dominant risks are financing and dilution. Jaguar has a long history of net losses, going-concern uncertainty, and repeated share issuance and reverse stock splits, and its market cap collapsed roughly 99% during 2025 into the low single-digit millions. Recurring product revenue is very small (about $1.2 million in Q1 2026), so the headline Q1 revenue was almost entirely a one-time license fee that will not repeat each quarter. The rare-disease pipeline is early and could fail in the clinic or with regulators. The business now depends on a single external partner, Future Pak, for US commercialization of its marketed products. As a micro-cap, the stock is thinly traded and highly volatile, and further capital raises or reverse splits remain possible. This is a speculative security where a total loss is a realistic outcome.

Jaguar Health, through its Napo Pharmaceuticals subsidiary, is a commercial-stage company centered on crofelemer, a plant-derived compound sourced from the Croton lechleri tree.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Future Pak license and non-dilutive cash) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risks are financing and dilution) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The speculative bull case is that the Future Pak license brings non-dilutive cash and a simpler, more focused business chasing rare-disease indications. The bear case is a tiny revenue base, a long history of losses, going-concern uncertainty, and repeated reverse splits and dilution that have wiped out most prior value. This is a high-risk micro-cap where a total loss is realistic, so size any position accordingly.

Jaguar Health is a commercial-stage pharmaceutical company built around crofelemer, a plant-derived compound. Its approved human product, Mytesi, treats noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and it has an animal-health arm and other products. It manufactures these treatments and is developing crofelemer for rare gastrointestinal diseases.

In January 2026 Jaguar out-licensed US marketing rights for Mytesi and Canalevia-CA1 to Woodward Specialty, an affiliate of privately held Future Pak, in a deal worth up to $38 million (roughly $18 million upfront plus milestones). Future Pak became the exclusive US marketer while Jaguar remains the manufacturer, giving Jaguar non-dilutive cash and letting it focus on rare-disease development.